Wall Street Zen cut shares of Coya Therapeutics (NASDAQ:COYA – Free Report) from a hold rating to a sell rating in a research report released on Saturday.
A number of other research firms have also weighed in on COYA. D. Boral Capital reaffirmed a “buy” rating and set a $15.00 target price on shares of Coya Therapeutics in a report on Friday, April 10th. Chardan Capital reaffirmed a “buy” rating and set a $14.00 target price on shares of Coya Therapeutics in a report on Monday, March 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Coya Therapeutics in a report on Monday, April 20th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Coya Therapeutics in a report on Monday, March 23rd. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.
Get Our Latest Research Report on COYA
Coya Therapeutics Stock Performance
Coya Therapeutics (NASDAQ:COYA – Get Free Report) last posted its earnings results on Tuesday, May 12th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.07. The business had revenue of $0.25 million during the quarter, compared to analyst estimates of $0.15 million. Coya Therapeutics had a negative return on equity of 55.86% and a negative net margin of 266.10%. Equities research analysts forecast that Coya Therapeutics will post -1.5 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of COYA. JPMorgan Chase & Co. purchased a new position in shares of Coya Therapeutics during the third quarter worth about $28,000. CIBC Private Wealth Group LLC purchased a new position in shares of Coya Therapeutics during the fourth quarter worth about $47,000. Occudo Quantitative Strategies LP purchased a new position in shares of Coya Therapeutics during the fourth quarter worth about $66,000. Lantern Wealth Advisors LLC purchased a new position in shares of Coya Therapeutics during the third quarter worth about $66,000. Finally, Oppenheimer & Co. Inc. purchased a new position in shares of Coya Therapeutics during the fourth quarter worth about $81,000. Hedge funds and other institutional investors own 39.75% of the company’s stock.
About Coya Therapeutics
Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.
Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.
Recommended Stories
- Five stocks we like better than Coya Therapeutics
- 3 Stocks to Own If Gas Prices Keep Rising
- 3 Crucial Aerospace Component Makers That Analysts Love
- Alphabet’s Googlebook Brings Gemini AI to PC Hardware
- Peloton Stock Gives Back Gains After Upbeat Earnings Report
Receive News & Ratings for Coya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
